Mitiglinide (calcium)

Mitiglinide Calcium (KAD-1229 anhydrous), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide Calcium is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel) . Mitiglinide Calcium can be used for the research of type 2 diabetes[1][2].

Product Specifications

CAS Number

[145525-41-3]

Product Name Alternative

KAD-1229 (anhydrous) ; S21403 (anhydrous)

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

Potassium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Mitiglinide-Calcium.html

Purity

98.82

Solubility

DMSO : 5 mg/mL (ultrasonic)

Smiles

O=C([O-])[C@H](CC(N1C[C@](CCCC2)([H])[C@]2([H])C1)=O)CC3=CC=CC=C3.[0.5Ca2+]

Molecular Formula

C19H24NO3.1/2Ca

Molecular Weight

334.44

Precautions

H302, H315, H319, H335

References & Citations

[1]Y Sunaga, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol. 2001 Nov 9;431 (1) :119-25.|[2]Kiyoshi Ichikawa, et al. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. Clin Exp Pharmacol Physiol. May-Jun 2002;29 (5-6) :423-7.